Get the Stockscreener App
42.48
0.63%
0.265
After Hours:
42.46
-0.015
-0.04%
Liquidia Corp stock is traded at $42.48, with a volume of 1.42M.
It is up +0.63% in the last 24 hours and up +23.44% over the past month.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
See More
Previous Close:
$42.21
Open:
$42.31
24h Volume:
1.42M
Relative Volume:
0.72
Market Cap:
$3.70B
Revenue:
$19.32M
Net Income/Loss:
$-141.47M
P/E Ratio:
-25.21
EPS:
-1.6851
Net Cash Flow:
$-120.48M
1W Performance:
+7.91%
1M Performance:
+23.44%
6M Performance:
+116.71%
1Y Performance:
+203.18%
1-Day Range:
$41.56
$43.42
1-Week Range:
$38.68
$43.42
52-Week Range:
$11.26
$43.42
Liquidia Corp Stock (LQDA) Company Profile
Name
Liquidia Corp
Sector
Industry
Phone
919.328.4400
Address
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Compare LQDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
42.48 | 3.67B | 19.32M | -141.47M | -120.48M | -1.6851 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Resumed | Jefferies | Buy |
| May-19-25 | Downgrade | Oppenheimer | Perform → Underperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-16-24 | Initiated | Raymond James | Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Perform |
| Jan-05-24 | Reiterated | Needham | Buy |
| Sep-19-22 | Resumed | Wedbush | Underperform |
| Sep-01-22 | Downgrade | Wedbush | Neutral → Underperform |
| Jul-22-22 | Initiated | Ladenburg Thalmann | Buy |
| May-31-22 | Initiated | BTIG Research | Buy |
| May-26-22 | Initiated | BofA Securities | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Nov-20-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-05-18 | Initiated | Wedbush | Outperform |
| Aug-20-18 | Initiated | Jefferies | Buy |
| Aug-20-18 | Initiated | Needham | Buy |
View All
Liquidia Corp Stock (LQDA) Latest News
Liquidia brings inhaled PAH, PH-ILD data to PVRI 2026 in Dublin - Stock Titan
Liquidia Options Trading: A Deep Dive into Market Sentiment - Benzinga
Inflation Data: What drives Liquidia Corporations stock price2025 Bull vs Bear & Safe Entry Momentum Tips - baoquankhu1.vn
Liquidia (NASDAQ:LQDA) Reaches New 52-Week HighTime to Buy? - MarketBeat
Liquidia Technologies stock hits all-time high at 41.77 USD - Investing.com
Liquidia Corporation (NASDAQ:LQDA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Institution Moves: Does Liquidia Corporation outperform in volatile marketsBear Alert & Stepwise Trade Execution Plans - baoquankhu1.vn
Liquidia Corp and MP Materials See Surge in Options Trading Volume - Intellectia AI
Liquidia Corporation (NASDAQ:LQDA) Short Interest Update - MarketBeat
Liquidia Corporation (NASDAQ:LQDA) Builds Platform-Driven Biopharma - Kalkine Media
Liquidia (NASDAQ:LQDA) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Campbell & CO Investment Adviser LLC Takes Position in Liquidia Corporation $LQDA - MarketBeat
Published on: 2026-01-17 14:39:47 - baoquankhu1.vn
Liquidia Target of Unusually Large Options Trading (NASDAQ:LQDA) - MarketBeat
Laughing Water Capital’s Updates on Liquidia Corp (LQDA) - Insider Monkey
Liquidia (NASDAQ:LQDA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Liquidia’s YUTREPIA Launch Turned A Small Biotech Into A Sales Story - Finimize
Liquidia Corporation (LQDA) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Liquidia (NASDAQ:LQDA) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
Liquidia’s chief business officer Adair sells $507k in LQDA stock - Investing.com Nigeria
Risk On: Is Liquidia Corporation stock ready for breakout2025 Price Targets & High Win Rate Trade Alerts - moha.gov.vn
Liquidia corp general counsel sells $1m in shares By Investing.com - Investing.com Nigeria
Liquidia corp general counsel sells $1m in shares - Investing.com
Liquidia (NASDAQ:LQDA) CFO Sells $1,382,364.76 in Stock - MarketBeat
Liquidia (NASDAQ:LQDA) Insider Sells $492,765.95 in Stock - MarketBeat
Liquidia (NASDAQ:LQDA) Insider Sells $791,345.06 in Stock - MarketBeat
Scott Moomaw Sells 20,533 Shares of Liquidia (NASDAQ:LQDA) Stock - MarketBeat
Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells 13,548 Shares of Stock - MarketBeat
Liquidia (NASDAQ:LQDA) CAO Sells $413,489.21 in Stock - MarketBeat
Liquidia Insider Sold Shares Worth $413,489, According to a Recent SEC Filing - marketscreener.com
Jefferies Raises Price Target for Liquidia (LQDA) to $55.00 with Buy Rating | LQDA Stock News - GuruFocus
Jefferies raises Liquidia stock price target to $55 on strong Yutrepia sales - Investing.com
Analyst Expectations For Liquidia's Future - Benzinga
BTIG reiterates Buy rating on Liquidia stock, maintains $49 price target - Investing.com
BTIG Reiterates Buy Rating for LQDA with $49 Target Price | LQDA Stock News - GuruFocus
Liquidia stock jumps after $148.3 million YUTREPIA sales update — what LQDA investors watch next week - TechStock²
Liquidia stock jumps after $148 mln Yutrepia sales update — what to watch next week - TechStock²
A Look At Liquidia (LQDA) Valuation After Strong YUTREPIA Sales And Cash Flow Update - Yahoo Finance
Why Liquidia (LQDA) Is Up 14.2% After YUTREPIA’s Cash-Generating 2025 Debut And Pipeline Push - Yahoo Finance
Liquidia (NASDAQ:LQDA) Raised to "Buy" at Wall Street Zen - MarketBeat
Liquidia (NASDAQ:LQDA) Sets New 1-Year High on Analyst Upgrade - MarketBeat
Is Liquidia Corp. overvalued or undervalued? - MarketsMojo
Why Liquidia Stock Rocked the Market Today - Finviz
Liquidia (LQDA) Shares Surge Over 18% Boosted by Market Activity - GuruFocus
Liquidia stock jumps nearly 15% after Yutrepia sales update, cash-flow claim - TechStock²
Liquidia (LQDA) Shares Decline 6.5% in Recent Trading - GuruFocus
Liquidia Technologies stock hits 52-week high at $36.45 - Investing.com
Liquidia stock holds steady as BTIG reiterates Buy rating on strong Yutrepia sales - Investing.com
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday - Benzinga
Liquidia stock surges after strong Q4 sales beat expectations By Investing.com - Investing.com Canada
Liquidia stock surges after strong Q4 sales beat expectations - Investing.com
Liquidia Corp Stock (LQDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Liquidia Corp Stock (LQDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Moomaw Scott | Chief Commercial Officer |
Jan 12 '26 |
Sale |
37.43 |
20,533 |
768,550 |
154,514 |
| Kaseta Michael | CFO and COO |
Jan 12 '26 |
Sale |
37.43 |
36,932 |
1,382,365 |
350,919 |
| Adair Jason | Chief Business Officer |
Jan 12 '26 |
Sale |
37.43 |
13,548 |
507,102 |
184,174 |
| Schundler Russell | General Counsel |
Jan 12 '26 |
Sale |
37.43 |
27,289 |
1,021,427 |
579,394 |
| JEFFS ROGER | Chief Executive Officer |
Jan 12 '26 |
Sale |
37.43 |
66,610 |
2,493,212 |
1,037,528 |
| Boyle Dana | Chief Accounting Officer |
Jan 12 '26 |
Sale |
37.43 |
11,047 |
413,489 |
156,700 |
| Saggar Rajeev | Chief Medical Officer |
Jan 12 '26 |
Sale |
37.43 |
21,142 |
791,345 |
176,883 |
| Schundler Russell | General Counsel |
Dec 01 '25 |
Sale |
32.19 |
1,072 |
34,508 |
577,288 |
| Krepp Sarah | Chief Human Resource Officer |
Dec 01 '25 |
Sale |
32.19 |
221 |
7,114 |
141,218 |
| Kaseta Michael | CFO and COO |
Dec 01 '25 |
Sale |
32.19 |
1,166 |
37,534 |
353,823 |
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):